XML 60 R50.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Commitments and Contingencies - HETLIOZ - Narrative (Details) - HETLIOZ® - USD ($) | 1 Months Ended | 3 Months Ended | 11 Months Ended | 12 Months Ended | 242 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 31, 2022 | Jan. 31, 2014 | Mar. 31, 2024 | Nov. 30, 2022 | Dec. 31, 2018 | Mar. 31, 2024
Commitments and Contingencies [Line Items] |  |  |  |  |  |
Acquisition of intangible assets |  | $ 8,000,000 |  |  | $ 25,000,000 | $ 37,500,000
Intangible assets capitalized |  |  |  |  |  | $ 33,000,000
Possible future milestone payment |  |  | $ 0 |  |  |
Royalty payment period |  |  | 10 years |  |  |
Percentage of future sublicense fees payable to third-party |  |  | mid-twenties |  |  |
Non-US |  |  |  |  |  |
Commitments and Contingencies [Line Items] |  |  |  |  |  |
Royalty payable percentage on net sales |  |  | 5.00% |  |  |
U.S. |  |  |  |  |  |
Commitments and Contingencies [Line Items] |  |  |  |  |  |
Royalty payable percentage on net sales | 5.00% |  |  | 10.00% |  |

X
- Definition Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | vnda_CommitmentsAndContingenciesLineItems
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property. + References No definition available. + Details
Name: | vnda_PercentageOfFutureSublicenseFeesPayable
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payable percentage under a contractual arrangement for use of technology or intellectual property. + References No definition available. + Details
Name: | vnda_RoyaltyPayableOnNetSalesPercentage
Namespace Prefix: | vnda_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Period + References No definition available. + Details
Name: | vnda_RoyaltyPeriod
Namespace Prefix: | vnda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vnda_HetliozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |